Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study
Asynchronous Messaging Therapy for Depression and Anxiety: A Longitudinal Study
1 other identifier
observational
12,980
0 countries
N/A
Brief Summary
Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness design. The aim of this study was to investigate the overall effectiveness of messaging therapy, identify any contributors to its effectiveness, and to evaluate a dosage effect for this type of treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2018
CompletedFirst Submitted
Initial submission to the registry
October 5, 2018
CompletedFirst Posted
Study publicly available on registry
October 9, 2018
CompletedFebruary 6, 2019
February 1, 2019
2.1 years
October 5, 2018
February 4, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change from Baseline in Depressive symptoms on the Patient Health Questionnaire - 9
Patient Health Questionnaire - 9 (PHQ-9) is a measure of depression symptoms. It has 9 items, with a minimum of 0 and a maximum of 27, with higher scores indicating more symptoms and distress. Decreasing scores indicate better outcome. All items are summed to give the summary score.
Up to 52 weeks
Change from Baseline in Anxiety symptoms on the Generalized Anxiety Disorder - 7
Generalized Anxiety Disorder - 7 (GAD-7) is a measure of anxiety symptoms. It has 7 items, with a minimum of 0 and a maximum of 21, with higher scores indicating more symptoms and distress. Decreasing scores indicate better outcome. All items are summed to give the summary score.
Up to 52 weeks
Secondary Outcomes (2)
Mean number of words sent from patient to therapist
Up to 52 weeks
Mean number of words sent from therapist to patient
Up to 52 weeks
Interventions
Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
Eligibility Criteria
Individuals seeking psychotherapy services through digitally-mediated application who present with and are diagnosed with a depression and/or anxiety related disorder.
You may qualify if:
- Diagnosed Depression and/or Anxiety Disorder
You may not qualify if:
- Any psychosis related symptoms or disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Talkspacelead
- Columbia Universitycollaborator
- New York Universitycollaborator
Related Publications (1)
Hull TD, Malgaroli M, Connolly PS, Feuerstein S, Simon NM. Two-way messaging therapy for depression and anxiety: longitudinal response trajectories. BMC Psychiatry. 2020 Jun 12;20(1):297. doi: 10.1186/s12888-020-02721-x.
PMID: 32532225DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matteo Malgaroli, PhD
New York University
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 5, 2018
First Posted
October 9, 2018
Study Start
January 1, 2016
Primary Completion
February 1, 2018
Study Completion
February 1, 2018
Last Updated
February 6, 2019
Record last verified: 2019-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- SAP
- Time Frame
- Data is available from October 10, 2018 to October 10, 2019
IPD for both studies is available in addition to the study protocol and statistical analysis plan. IPD includes demographic information for patient and therapist, as well as outcome scale summary scores for each time point.